Can you take phentermine and semaglutide together? Only if your prescriber decides it is right for you. The two have not been tested together in large clinical trials, and the phentermine label says combining it with other weight-loss drugs is not recommended because safety and effectiveness have not been established. Any combined use is off-label.
Written by Jen Adams, BSN, RN
Medically reviewed by Dr. Josh Allen, D.O., Medical Director, October 23, 2026
Disclaimer: This article is general education, not medical advice. Do not start, stop or combine any weight-loss medication without your prescriber. Individual results vary.
Phentermine and semaglutide both reduce appetite, but through different systems, which is why people ask about using them together. Phentermine is a sympathomimetic amine, a stimulant related to amphetamine, that acts on the central nervous system. Its label notes that appetite suppression may not be its only action, since other nervous system and metabolic effects may be involved.
Semaglutide is a GLP-1 receptor agonist. It acts on GLP-1 receptors in areas of the brain that regulate appetite and calorie intake, and it slows how fast the stomach empties. If you are on a compounded semaglutide program, keep in mind that compounded semaglutide is not FDA approved and has no FDA label of its own. The label facts on this page come from the FDA-approved semaglutide product for weight management.
| Phentermine | Semaglutide (weight management) | |
|---|---|---|
| Drug class | Sympathomimetic amine (stimulant) | GLP-1 receptor agonist |
| How it works | Acts on the central nervous system to reduce appetite | Acts on brain appetite centers; slows stomach emptying |
| Approved length of use | Short-term, “a few weeks,” per its label | Long-term weight reduction and maintenance |
| Controlled substance | Yes, Schedule IV | No |
| Side effects listed on the label (examples) | Fast heartbeat, palpitations, raised blood pressure, insomnia, restlessness, dry mouth | Nausea, diarrhea, vomiting, constipation, stomach pain |
| Combining with other weight-loss drugs | Not recommended; safety and effectiveness not established | Not with other semaglutide products or any other GLP-1 receptor agonist |
This table summarizes each label in general terms. It leaves out dosing on purpose, because your prescriber sets that for you.
The phentermine label addresses combination use directly. It says phentermine is indicated only as short-term monotherapy, meaning a single medication, and that the safety and efficacy of combining it with any other drug product for weight loss, including prescription drugs, over-the-counter products and herbal products, have not been established. It concludes that using phentermine with these products is not recommended, and it repeats this in the information patients must be given.
The current label for semaglutide for weight management does not mention phentermine. Its limitations of use say it should not be combined with other semaglutide-containing products or with any other GLP-1 receptor agonist. The first version of the label, from 2021, also said its safety and effectiveness with other weight-loss products had not been established.
Research is thin. We found no published clinical trial of phentermine with semaglutide. The closest study is a 12-week pilot trial of 45 adults who had already lost weight on liraglutide, another GLP-1 medication. Adding phentermine appeared well tolerated, but it did not produce additional clinically meaningful weight loss compared with placebo. One small study cannot show that the combination is safe for you.
A licensed provider reviews your full medication list before any plan, in person or by telehealth.
$425 a month, or $1,800 for a 6 to 8 month program
Each medication has its own side effects, and because the pair has not been studied in large trials, nobody can say exactly how the risks add up when they are used together.
Phentermine’s label lists cardiovascular effects such as palpitations, a fast heartbeat and raised blood pressure, plus overstimulation, restlessness, insomnia, dizziness, headache and dry mouth. It warns that rare cases of primary pulmonary hypertension and serious heart valve disease have been reported, mainly when phentermine was combined with fenfluramine or dexfenfluramine, and that a link with phentermine alone cannot be ruled out. It also carries a risk of abuse and dependence.
Semaglutide’s most common side effects are digestive: nausea, diarrhea, vomiting, constipation and stomach pain. Its label also lists increases in resting heart rate, along with warnings about pancreatitis, gallbladder problems and dehydration that can affect the kidneys.
If you have diabetes, both labels matter. The phentermine label says your insulin or diabetes medicines may need to be reduced. The semaglutide label warns that low blood sugar is more likely when it is used with insulin or medicines that make the body release insulin. Our guide to semaglutide and blood sugar explains what to watch for.
If you have any history of heart or blood pressure problems, talk with your prescriber about phentermine’s stimulant effects before adding it to any weight-loss plan.
The phentermine label lists conditions in which phentermine should not be used at all, whatever else you take. According to the label, do not use phentermine if you:
Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or by anyone who has had a serious allergic reaction to semaglutide. Our page on who should not take semaglutide covers this in more detail. If either medication is ruled out for you, it stays ruled out whether it is used alone or with the other.
Tirzepatide acts on both the GIP and GLP-1 pathways, and people ask the same question about it. The phentermine label’s caution covers any weight-loss drug, not a named medication, so its “not recommended” language applies to tirzepatide too. The current tirzepatide label for weight management says it should not be combined with other tirzepatide products or with any GLP-1 receptor agonist. We found no published clinical trial of phentermine with tirzepatide. For more on tirzepatide’s own risks, see our guide to tirzepatide safety.
Before considering phentermine alongside semaglutide or tirzepatide, ask your provider directly:
Only your prescriber can decide. The combination has not been tested in large clinical trials, and the phentermine label says using it with any other weight-loss drug is not recommended because safety and effectiveness have not been established. Any combined use would be off-label. The one small published trial of phentermine with a GLP-1 medication used liraglutide, not semaglutide, and found no meaningful extra weight loss.
No large study has shown the combination to be safe, so its safety for you depends on your health history and your prescriber’s judgment. Your prescriber would need to review your heart health, blood pressure, thyroid history, mental health and any diabetes medicines. Never add phentermine to semaglutide, or the other way around, on your own or with medication from another source.
Phentermine is approved only as a short-term treatment, described on its label as “a few weeks,” alongside diet, exercise and behavior changes. It is not approved for continuous long-term use the way semaglutide for weight management is. The label also says that if its appetite effect wears off, phentermine should be stopped rather than taken in larger amounts. Your prescriber decides what is appropriate for you.
Phentermine can raise heart rate and blood pressure, and its label lists palpitations and a fast heartbeat. The semaglutide label also lists increases in resting heart rate. How these effects combine has not been studied. People with heart disease or uncontrolled high blood pressure should not take phentermine at all, so your prescriber should review your heart history before considering it.
Most of the warnings on the phentermine label involve the heart and blood vessels: raised blood pressure, a fast heartbeat and, rarely, heart valve disease and high blood pressure in the lungs. The label also advises caution in people with reduced kidney function, because phentermine leaves the body through the urine. Report chest pain, shortness of breath, fainting or swelling in your legs to your prescriber right away.
The semaglutide label says not to combine it with other semaglutide products or any other GLP-1 receptor agonist. Low blood sugar is more likely with insulin or medicines that make the body release insulin, so those medicines may need to be reduced. Because semaglutide slows stomach emptying, it can also affect how some pills are absorbed. Share your full medication list with your prescriber.
The same caution applies. The phentermine label’s “not recommended” language covers any other weight-loss drug, including tirzepatide, and we found no published clinical trial of the two together. The tirzepatide label says not to combine it with other tirzepatide products or any GLP-1 receptor agonist. Only your prescriber can weigh the risks for you.
The phentermine label says combining it with other weight-loss drugs is not recommended, and no large trial has tested phentermine with semaglutide, so this is not a decision to make on your own. At InjectCo, a licensed prescriber working under Dr. Josh Allen, D.O., Medical Director, reviews every patient’s full health history and medication list before recommending a weight-loss plan. Bring your questions, and your complete medication list, to your consultation.
Bring your full medication list; we review it before recommending any plan.
$425 a month, or $1,800 for a 6 to 8 month program
